Cullinan Therapeutics Presents Preclinical Data for CLN-978
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) will present new preclinical data for CLN-978 at the American College of Rheumatology (ACR) Convergence 2025.
CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases.
- Presentation: Poster Session C, Poster Number 2293, October 28, 10:30 a.m.-12:30 p.m. CT
- Location: Booth (#1074) in the Exhibit Hall, Chicago, Illinois
CLN-978, its novel investigational CD19xCD3 bispecific T cell engager.
Cullinan Therapeutics is a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer.
Author's summary: Cullinan Therapeutics presents preclinical data for CLN-978 at ACR Convergence 2025.
More News
- iOS 26.1 Coming Soon: New Features for Your iPhone and Release Date
- Community pharmacies and BioPharma: Advancing whole-patient care together
- Pirates Top 30 Prospects No. 15: Zander Mueth Set Back By Injuries
- Renters’ Rights Bill does not protect tenants only council budgets warns expert
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- Early TNF Inhibitor Use Improves Outcomes in Nonsystemic JIA
- Guildford Dragon NEWS
- Delirium Risk Increased for Seniors Prescribed First-Generation Antihistamines
- Abbott Told to Provide Prescribing Details, Supporting Data for Triamcinolone Hexacetonide Pre-Filled Syringe
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado